Novel Therapies for ANCA-associated Vasculitis

医学 ANCA相关性血管炎 血管炎 内科学 肉芽肿伴多发性血管炎 皮肤病科 痹症科 重症监护医学 疾病
作者
Sara Monti,Fabio Brandolino,Alessandra Milanesi,Blerina Xoxi,Paolo Delvino,Carlomaurizio Montecucco
出处
期刊:Current Rheumatology Reports [Springer Science+Business Media]
卷期号:23 (6): 38-38 被引量:50
标识
DOI:10.1007/s11926-021-01010-0
摘要

The purpose of this review is to discuss the most recent evidence on the treatment innovations and future prospective in the management of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs). In AAV, a growing body of research is available on novel treatment options for remission induction and to clarify some uncertainties concerning the optimal use of available drugs. Efforts are being made to reduce the toxicity associated with high-dose, prolonged glucocorticoids (GC) regimens. Despite major advances in the prognosis of AAV, relapses are still common and the intensity and duration of remission treatment constitute a great challenge in the management of these chronic conditions. A paradigm shift in practice in the management of AAV is being supported by recent evidence suggesting the comparable efficacy and improved safety profile of schemes with a reduced dose of GC for the induction and maintenance of remission in patients with severe granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Moreover, recent appraisal of pathogenetic mechanisms, including complement activation pathways, has introduced the revolutionary concept of an alternative to GC, such as avacopan. Plasma exchange failed to prevent end-stage renal disease and mortality in patients with severe renal involvement or pulmonary haemorrhage according to a large multicentre randomised trial. Intensified immunosuppressive strategies for patients with life-threatening manifestations, including the combination of rituximab (RTX) with cyclophosphamide (CYC) have revealed promising preliminary data. New evidence for the use of alternative immunosuppressive agents (e.g. mycophenolate mofetil or abatacept) for the induction of remission in patients with non-severe disease is emerging. Several studies have been recently published, or are ongoing, to assess the optimal strategy and duration of maintenance of remission with the available treatment options (GC, azathioprine, and RTX). Preliminary evidence supports the superiority of a more prolonged course of maintenance treatment. The management of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) has been improved by the recent demonstration of efficacy and safety of an interleukin-5 inhibitor, mepolizumab. Ongoing randomised studies will clarify the role of RTX in patients with severe manifestations of EGPA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JoJo完成签到,获得积分10
刚刚
star完成签到,获得积分10
3秒前
3秒前
小贾完成签到,获得积分10
4秒前
杀死周一完成签到,获得积分10
6秒前
tina酱完成签到 ,获得积分10
8秒前
zhangyiyang完成签到 ,获得积分10
8秒前
隐形骁完成签到,获得积分10
8秒前
9秒前
16601107082发布了新的文献求助10
10秒前
liuchang完成签到 ,获得积分10
10秒前
22336完成签到,获得积分0
10秒前
Lemenchichi完成签到,获得积分10
10秒前
老实的鑫磊完成签到,获得积分20
11秒前
会过期的凤梨完成签到 ,获得积分10
12秒前
hahaha完成签到 ,获得积分10
12秒前
wailwq完成签到 ,获得积分10
13秒前
13秒前
13秒前
怕黑的冰安完成签到,获得积分10
14秒前
大卫戴完成签到 ,获得积分10
14秒前
临天下完成签到,获得积分10
14秒前
小楞楞完成签到,获得积分10
15秒前
tanfor完成签到 ,获得积分10
16秒前
孤星发布了新的文献求助10
16秒前
Matthewwt完成签到,获得积分10
16秒前
hyd完成签到,获得积分10
17秒前
123完成签到,获得积分10
17秒前
大个的应助被16601107082采纳,获得10
18秒前
orixero的应助被仔仔在采纳,获得10
19秒前
123完成签到 ,获得积分10
20秒前
甜美的盼晴完成签到 ,获得积分10
20秒前
xiuxue424完成签到,获得积分10
20秒前
郑丽琴完成签到 ,获得积分10
21秒前
梦安完成签到 ,获得积分10
21秒前
HHH完成签到 ,获得积分10
21秒前
小龙仔123完成签到 ,获得积分10
21秒前
尼斯湖中的小水怪完成签到 ,获得积分10
22秒前
DearRy完成签到 ,获得积分10
22秒前
邱继鹏完成签到,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166570
求助须知:如何正确求助?哪些是违规求助? 9559581
关于积分的说明 21750904
捐赠科研通 7757397
什么是DOI,文献DOI怎么找? 3429170
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923